Metastatic Clinical Trials in Shenzhen, Guangdong

30 recruitingShenzhen, Guangdong, China

Showing 120 of 30 trials

Recruiting
Phase 2Phase 3

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Metastatic Pancreatic Ductal AdenocarcinomaCachexia
Pfizer982 enrolled188 locationsNCT06989437
Recruiting
Phase 2Phase 3

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Advanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer
Mirati Therapeutics Inc.626 enrolled770 locationsNCT04613596
Recruiting
Phase 2Phase 3

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb590 enrolled311 locationsNCT07063745
Recruiting
Phase 3

Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Metastatic Pancreatic Ductal Adenocarcinoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.566 enrolled71 locationsNCT07165951
Recruiting
Phase 1Phase 2

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Metastatic Solid TumorsLocally Advanced Solid Tumors
Turning Point Therapeutics, Inc.500 enrolled165 locationsNCT03093116
Recruiting

Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns

Metastatic Breast Cancer
Sun Yat-sen University800 enrolled26 locationsNCT06551220
Recruiting
Phase 1Phase 2

A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer

Pancreatic Cancer Metastatic
Junjie Hang23 enrolled1 locationNCT07040228
Recruiting
Phase 1Phase 2

PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors

Advanced or Metastatic Solid Tumors
Beijing Biotech60 enrolled1 locationNCT07510828
Recruiting
Phase 1Phase 2

Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC

Triple-Negative Breast CancerHER2-positive Breast CancerBreast Cancer (Advanced/Metastatic)
Beijing Biotech60 enrolled1 locationNCT07510802
Recruiting
Phase 1Phase 2

Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC

Metastatic Liver CancerAdvanced Hepatocellular Carcinoma (HCC)
Beijing Biotech30 enrolled1 locationNCT07500220
Recruiting
Phase 1

Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma

Urothelial CarcinomaLocally Advanced Urothelial CarcinomaMetastatic Urothelial Carcinoma+2 more
Beijing Biotech42 enrolled1 locationNCT07492628
Recruiting
Phase 1Phase 2

Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)

HER2-positive Breast CancerTriple Negative Breast Cancer(TNBC)Breast Cancer (Locally Advanced or Metastatic)
Beijing Biotech60 enrolled1 locationNCT07486089
Recruiting
Phase 1Phase 2

Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Adenocarcinoma (PDAC)Unresectable Locally Advanced or Metastatic Disease
Beijing Biotech42 enrolled1 locationNCT07480928
Recruiting
Phase 1Phase 2

Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer

Colorectal Cancer MetastaticAdenocarcinoma of Colon
Beijing Biotech48 enrolled1 locationNCT07462650
Recruiting
Phase 1Phase 2

Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC

Non-small Cell Lung CancerAdvanced/Metastatic NSCLC
Beijing Biotech48 enrolled1 locationNCT07467863
Recruiting
Early Phase 1

Universal CAR-T Cells (REVO-UWD-01) for Metastatic Colorectal Cancer

Metastatic Colorectal CancerCRC (Colorectal Cancer)
Wondercel Biotech (ShenZhen)30 enrolled2 locationsNCT06653010
Recruiting
Early Phase 1

Autologous CAR-T Cells (WD-01) for Metastatic Colorectal Cancer

Metastatic Colorectal CancerCRC (Colorectal Cancer)
Wondercel Biotech (ShenZhen)30 enrolled2 locationsNCT06675513
Recruiting
Phase 3

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Advanced Non-squamous Non-small-cell Lung CancerMetastatic Non-Squamous Non-Small Cell Lung Cancer
Allist Pharmaceuticals, Inc.392 enrolled37 locationsNCT06416410
Recruiting
Phase 1Phase 2

Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer

Metastatic Colorectal Cancer
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center30 enrolled1 locationNCT06776757
Recruiting
Phase 3

Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

Metastatic Breast Cancer
Herui Yao210 enrolled13 locationsNCT04263298